C6orf62: A Promising Drug Target and Biomarker for Chromosome 6 Open Reading Frame 62

Target Name: C6orf62

NCBI ID: G81688

C6orf62

C6orf62: A Promising Drug Target and Biomarker for Chromosome 6 Open Reading Frame 62

Introduction

Chromosome 6 (C6) is one of the human chromosomes that are prone to genetic mutations, including copy number variations, gene fusions, and deletions. copy number variation (CNV) are among the most common genetic alterations observed in cancer. According to the World Health Organization (WHO), CNVs account for approximately 10% of all cancer cases. Chromosome 6 open reading frame (C6ORF62) is a gene located on chromosome 6 that has been identified as a potential drug target and biomarker for various diseases, including cancer.

C6ORF62: A Potential Drug Target

C6ORF62 is a gene that encodes a protein known as CDK6 (chromosome-specific DNA binding protein 6). CDK6 is a transcription factor that plays a crucial role in the regulation of gene expression and DNA replication. Mutations in the CDK6 gene have been linked to various diseases, including cancer.

C6ORF62 has been shown to be a potential drug target for various diseases, including cancer. For instance, studies have shown that inhibition of CDK6 can lead to regression of various types of cancer, including breast, ovarian, and prostate cancers. Additionally, overexpression of CDK6 has been shown to promote the growth and survival of various cancer cells.

C6ORF62 as a Biomarker

C6ORF62 has also been identified as a potential biomarker for various diseases, including cancer. The expression of CDK6 has been shown to be elevated in various types of cancer, including breast, ovarian, and prostate cancers. Additionally, the expression of CDK6 has been shown to be associated with the poor prognosis of cancer patients.

C6ORF62 has been shown to be a potential biomarker for various diseases, including cancer. The expression of CDK6 has been shown to be elevated in various types of cancer, including breast, ovarian, and prostate cancers. Additionally, the expression of CDK6 has been shown to be associated with the poor prognosis of cancer patients.

Conclusion

In conclusion, C6ORF62 is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. The expression of CDK6 has been shown to be elevated in various types of cancer, including breast, ovarian, and prostate cancers, and has been associated with the poor prognosis of cancer patients. Further research is needed to confirm its potential as a drug target and biomarker.

Protein Name: Chromosome 6 Open Reading Frame 62

The "C6orf62 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C6orf62 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets